Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Roche Diagnostics extends HCV immunoassay availability

Roche Diagnostics : 09 April, 2008  (New Product)
Roche Diagnostics’ Elecsys Anti-HCV (Hepatitis C Virus) assay has received regulatory approval in Europe for the E 170 analyser for Modular Analytics and the e 601 module for the cobas 6000 platform.
The Elecsys Anti-HCV Assay is already available on the Elecsys 2010 and the cobas e 411 instruments.

Hepatitis C virus (HCV) infection represents a major cause of death through the development of severe fibrosis, cirrhosis and liver cancer. The principal mode of transmission is parenteral exposure to infected blood or blood products that result from insufficient blood screening procedures mainly in developing countries, and contaminated needles or other invasive medical tools. Most people with hepatitis C became infected through blood transfusions received before 1992, the year when improved blood screening tests became available.

Acute Hepatitis C infection is often asymptomatic and many people are unaware that they are infected until they present with the complications of liver disease. Therefore elevated liver enzymes are often the first signs of chronic HCV infection. HCV antibody tests are used for the primary diagnosis of hepatitis C virus infection in patients with suspected liver disease.

'The addition of anti-HCV Assay to the E 170 analyzer for Modular Analytics and the e601 module for the cobas 6000 platform complements Roche's already comprehensive menu of hepatitis immunodiagnostic and liver function assays, all of which can be accurately and simultaneously measured on a single blood sample to identify the underlying liver disorder,' said Dirk Ehlers, head of Roche Professional Diagnostics. 'The addition of the E 170/cobas e 601 application for Anti-HCV is another important step in demonstrating Roche's commitment to addressing our customers needs in terms of laboratory efficiency and convenience.'

The Elecsys Anti-HCV test will be available internationally upon approval of the local regulatory agencies.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo